Bilbao
In ‘Hora 14 Euskadi’, Dr. Guillermo López Vivanco, specialist in Medical Oncology and current head of the service at the Quirónsalud Bizkaia Hospital, at the Cruces University Hospital and coordinator of the Biocruces Medical Oncology Group, has highlighted the importance of intelligence artificial in the fight against breast cancer.
Guillermo López Vivanco has explained that, although AI still needs more development to be routinely implemented in clinical practice, its potential is immense: “Artificial intelligence covers many areas of our lives, but in health, its use in diagnosis Early detection and personalized treatments are advancing in leaps and bounds. The doctor emphasizes that this technology is particularly relevant in visual diagnoses, such as breast cancer, where AI can make ultrasounds, mammograms and MRIs faster, more accurate and more efficient. .
López Vivanco has also spoken about the advance of AI in the field of oncology research. At the national level, he points out that, although its use in routine care is still in the development phase, artificial intelligence already plays a fundamental role in clinical studies and trials: “Although its development has been slow, we now have the ability to process data in a way that allows us to generate algorithms that can identify precise patterns, which is essential in the early detection of diseases.”
The oncologist mentions that some studies already indicate that AI could detect breast cancer “up to five years before it develops.” These types of advances, he assures, “are very close to becoming a reality,” which will allow much earlier and more precise diagnoses.
Additionally, López Vivanco highlights the impact of AI in cancer treatment, from drug manufacturing to precision medicine. “AI will not only help us develop more effective drugs, but will also facilitate the search for new therapeutic targets, thus improving the quality of treatments,” he explained. He adds that, with AI, “the mechanisms are more precise and clinical trials can offer more reliable and faster results.”
With AI at the forefront of oncology, López Vivanco reiterates the need to continue advancing in the development of this technology so that, in the near future, patients can benefit from more precise diagnoses and personalized treatments: “We are at a point where that technology can significantly improve survival rates and quality of life for cancer patients.
Euskadi, according to the doctor, continues to be “a national benchmark in genetic studies and early detection tests”, which underlines the importance of continuing to invest in the research and development of innovative tools such as artificial intelligence.
